Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy (FORTIS)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
First received: July 5, 2011
Last updated: March 11, 2016
Last verified: March 2016
The investigators plan to conduct a nurse-based telephone intervention study to minimize toxicity and increase compliance to a combination of Fludarabine-Cyclophosphamide-Rituximab (FCR) given frontline to Chronic Lymphocytic Leukemia patients.

Condition Intervention Phase
Chronic Lymphocytic Leukemia
Other: Telephone Intervention
Other: Usual Practice
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Facing Obstacles to RDI(Relative Dose Intensity)Through Telephone Intervention Strategy

Resource links provided by NLM:

Further study details as provided by University Hospital, Toulouse:

Primary Outcome Measures:
  • Evaluation of RDI [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Reductions in Relative Dose Intensity, calculated as the difference between initially planned doses of F, C and R and effectively prescribed doses of the 3 drugs, before and after 6 courses of FCR.

Secondary Outcome Measures:
  • Evaluation of Toxicity grade III-IV [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    rate of grade III-IV toxicities (neutropenia, fever, infections, renal insufficiency), assessment of quality of life and psychological comfort during FCR therapy.

Enrollment: 60
Study Start Date: September 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Without AMA
Patient will be follow only like usual practice
Other: Usual Practice
None, only usual practice.
With AMA
Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
Other: Telephone Intervention
Only for arm AMA, patient will have one phone every week to evaluate physical conditions.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. CLL whatever Binet stage, but with at least one NCIWG2008 criteria indicating a need for first line treatment.

    • Matutes score must be 4-5/5.
    • Initial cytopenia (due to CLL) are not exclusion criteria.
    • Lymph node biopsy is needed only if suspicion of Richter syndrome.
    • Mandatory pre-therapeutic check-up: FISH in search for deletion del17p and del11q, DAT test, haptoglobin levels, creatinine clearance.
  2. Eligibility to a treatment with FCR: clearance > 60ml/mn, consider dose adjustments (recommended by protocol) if clearance30-60ml/mn, and comorbidity score CIRS-G≤11.
  3. Signed informed consent
  4. Age> or equal 18 years, ECOG PS 0-2.
  5. Estimated overall survival>6 months.
  6. Conserved liver function (bilirubin<2,5mg/dl, SGPT<4ULN, SGOT<4ULN) except infiltration due to the disease.
  7. Contraception for younger patients.
  8. Confident with the use of telephone, no disabling deafness.

Exclusion Criteria:

  1. Richter syndrome or atypical CLL (Matutes score <4), and/or del17p by FISH
  2. Relapse of CLL
  3. Contra-indications to fludarabine: auto-immune cytopenia, creatinine clearance<30 ml/mn.
  4. Serologies positive for HIV, HBV, or HCV. No active bacterial, viral or fungal infection
  5. Previous history of hypersensibility to any product used in this protocol
  6. Denial, or medical or psychological condition preventing completion of the signed informed consent.
  7. Treatment with an investigational agent, or participation to another therapeutic protocol, 30 days before participating to this study.
  8. Pregnant/breastfeeding women.
  9. CNS involvement by CLL.
  10. Presence of another cancer needing treatment (except basocellular carcinoma or cervix cancer managed with only surgery or local therapy).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01393366

Centre Hospitalier de la côte basque
Bayonne, France, 64109
CH Saint Jean
Perpignan, France, 66046
CHU Purpan
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Toulouse
Principal Investigator: Loïc YSEBAERT, MD University Hospital Of Toulouse
  More Information

Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT01393366     History of Changes
Other Study ID Numbers: 1030903 
Study First Received: July 5, 2011
Last Updated: March 11, 2016
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on May 30, 2016